Pegylated interferon-alfa plus ribavirin therapies for chronic hepatitis C

Authors

  • T Kanda Department of Gastroenterology, Chiba University Hospital, and Department of Medicine and Clinical Oncology,ChibaUniversity, Graduate School of Medicine
  • O Yokosuka Department of Gastroenterology, Chiba University Hospital, and Department of Medicine and Clinical Oncology,Chiba University, Graduate School of Medicine

DOI:

https://doi.org/10.31729/jnma.44

Abstract

Until HCV NS3/4A protease inhibitors become available at the end of 2011, the combination pegylated-interferon (PEG-IFN)-alfa and ribavirin (RBV) will remain the standard treatment for chronic hepatitis C patients. In some hepatitis C virus-infected patients, PEG-IFN plus RBV treatment against HCV should continue to be used because of side effects of new drugs such as anemia. Our Japanese experiences should provide new information for the treatment of chronic hepatitis C. 

Keywords: Direct-acting antiviral agents (DAA), HCV, pegylated interferon, ribavirin, standard of care (SOC ).

Downloads

Published

2011-03-31

How to Cite

Kanda, T., & Yokosuka, O. (2011). Pegylated interferon-alfa plus ribavirin therapies for chronic hepatitis C. Journal of Nepal Medical Association, 51(181). https://doi.org/10.31729/jnma.44

Issue

Section

Case Reports